Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PNT
PNT logo

PNT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
1.33B
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Show More

Events Timeline

(ET)
2025-12-17
20:00:00
Paranovus Entertainment Technology Ltd Trading Halted, News Pending
select

News

Businesswire
9.5
2025-03-04Businesswire
CPI Card Group Inc. Reports Fourth Quarter and Full Year 2024 Results
  • Financial Performance: CPI Card Group reported a 22% increase in fourth-quarter net sales to $125.1 million and a 148% rise in net income to $6.8 million, driven by strong prepaid business performance and contactless card sales. For the full year, net sales grew 8% to $480.6 million, but net income decreased 19% due to debt refinancing costs.

  • 2025 Outlook: The company projects mid-to-high single-digit growth for both net sales and Adjusted EBITDA in 2025, focusing on expanding into new markets and enhancing digital offerings while anticipating slightly lower Free Cash Flow compared to 2024 due to increased capital spending and cash interest payments.

Businesswire
2.0
2025-02-10Businesswire
CPI Card Group Inc. to Release Fourth Quarter and Full Year 2024 Results on March 4, 2025
  • Upcoming Conference Call: CPI Card Group Inc. will host a webcast and conference call on March 4, 2025, at 9:00 a.m. ET to discuss its fourth quarter 2024 financial results, with participation from CEO John Lowe and CFO Jeff Hochstadt.

  • Accessing the Call: The call can be accessed via telephone or online, and a replay will be available until March 18, 2025, along with a webcast replay on the company's Investor Relations website.

Businesswire
9.5
2024-11-05Businesswire
CORRECTING and REPLACING CPI Card Group Inc. Reports Third Quarter 2024 Results
  • Financial Performance Overview: CPI Card Group Inc. reported an 18% increase in net sales to $125 million for Q3 2024, driven by demand for debit and credit cards, but net income fell by 66% due to debt refinancing costs. The company anticipates mid-to-high single-digit growth in net sales and low single-digit growth in Adjusted EBITDA moving forward.

  • Market Position and Strategy: The company has sold over 100 million eco-focused payment cards and expanded its market strategy to include digital solutions, with a focus on contactless payments and eco-friendly products, while also managing increased operational costs and challenges related to customer retention and supply chain disruptions.

Businesswire
9.5
2024-11-05Businesswire
CPI Card Group Inc. Reports Third Quarter 2024 Results
Businesswire
8.5
2024-10-01Businesswire
CPI Card Group Inc. Announces Pricing of Secondary Public Offering of Common Stock
  • CPI Card Group Offering: CPI Card Group Inc. announced a secondary public offering of 1,200,000 shares of common stock at $21.00 per share, with total gross proceeds expected to be approximately $25.2 million for the selling stockholders, not including any proceeds for the company itself.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the offering's closing and proceeds, highlighting potential risks and uncertainties that could affect actual results.

Businesswire
8.5
2024-09-30Businesswire
CPI Card Group Inc. Announces Proposed Secondary Public Offering of 1,000,000 Shares of Common Stock by Majority Stockholder
  • Stock Offering Announcement: CPI Card Group Inc. has announced an underwritten secondary public offering of 1,000,000 shares of common stock by certain stockholders affiliated with Parallel49 Equity, with an option for underwriters to purchase an additional 150,000 shares.

  • Company Background and Forward-Looking Statements: The company specializes in payments technology and provides various card solutions, while also cautioning that the offering's completion is subject to market conditions and other uncertainties.

Wall Street analysts forecast PNT stock price to rise
0 Analyst Rating
Wall Street analysts forecast PNT stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
Cantor Fitzgerald
Carter Gould
Buy
Initiates
$975
AI Analysis
2025-04-22
Reason
Cantor Fitzgerald
Carter Gould
Price Target
$975
AI Analysis
2025-04-22
Initiates
Buy
Reason
Guggenheim
Seamus Fernandez
Strong Buy
Maintains
$973 → $928
2025-04-14
Reason
Guggenheim
Seamus Fernandez
Price Target
$973 → $928
2025-04-14
Maintains
Strong Buy
Reason

Valuation Metrics

The current forward P/E ratio for POINT Biopharma Global Inc. (PNT.O) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess POINT Biopharma Global Inc.'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
Current PE
NaN
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
Current EV/EBITDA
NaN
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
Current PS
NaN
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding PNT

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is POINT Biopharma Global Inc. (PNT) stock price today?

The current price of PNT is 0 USD — it has increased 0

What is POINT Biopharma Global Inc. (PNT)'s business?

POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.

What is the price predicton of PNT Stock?

Wall Street analysts forecast PNT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PNT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is POINT Biopharma Global Inc. (PNT)'s revenue for the last quarter?

POINT Biopharma Global Inc. revenue for the last quarter amounts to NaN USD, decreased

What is POINT Biopharma Global Inc. (PNT)'s earnings per share (EPS) for the last quarter?

POINT Biopharma Global Inc.. EPS for the last quarter amounts to USD, decreased

How many employees does POINT Biopharma Global Inc. (PNT). have?

POINT Biopharma Global Inc. (PNT) has 129 emplpoyees as of April 04 2026.

What is POINT Biopharma Global Inc. (PNT) market cap?

Today PNT has the market capitalization of 1.33B USD.